Literature DB >> 34714169

Invasion of a Recurrent Laryngeal Nerve from Small Well-Differentiated Papillary Thyroid Cancers: Patient Selection Implications for Active Surveillance.

Samantha K Newman1, Victoria Harries2, Laura Wang2, Marlena McGill2, Ian Ganly2, Jeffrey Girshman3, R Michael Tuttle1.   

Abstract

Background: The success of an active surveillance management approach to low-risk papillary thyroid cancer (PTC) is heavily dependent on proper patient selection. For example, primary tumors located in a subcapsular position immediately adjacent to the trachea or a recurrent laryngeal nerve (RLN) are considered to be inappropriate for active surveillance. Since preoperative imaging cannot reliably rule out extrathyroidal extension or reveal the full course of the RLN relative to the thyroid gland, it is important for clinicians to understand subcapsular tumor locations and minimum tumor sizes that are most likely to be associated with gross invasion of the RLNs.
Methods: We assessed the medical records of 123 patients treated at Memorial Sloan Kettering Cancer Center (MSK) between 1986 and 2015 who had a primary PTC tumor demonstrating gross extrathyroidal extension to either the right or left RLN. Thirty patients with a primary tumor ≤2 cm in diameter demonstrating extrathyroidal extension into an RLN were included in the analysis.
Results: Gross invasion of an RLN by tumors ≤2 cm is a rare event that was seen in only 0.8% (35/4334) of patients with PTC who underwent initial thyroid surgery at MSK between 1986 and 2015. Gross RLN invasion was associated with subcapsular PTC tumors located in either the right paratracheal area (60%), left paratracheal area (36.7%), or right lateral posterior lobe area not adjacent to the trachea (3.3%). Only a quarter of the patients had imaging findings suggestive of extrathyroidal extension and only 30% had clinically apparent vocal paresis/paralysis on preoperative examination. Invasion of the RLN was not observed for primary tumors <0.9 cm in diameter, regardless of tumor location. Conclusions: Well-differentiated PTC tumors ≥0.9 cm in maximal diameter that are located in the right paratracheal, left paratracheal, and right lateral posterior lobe subcapsular positions are usually not appropriate for active surveillance even in the absence of definitive evidence for nerve invasion on preoperative imaging or vocal cord examination. Patient selection for active surveillance management should take into account not only the size and growth rate of a tumor but also its location in relation to the expected course of RLNs.

Entities:  

Keywords:  active surveillance; cancer; papillary; thyroid; well-differentiated

Mesh:

Year:  2021        PMID: 34714169      PMCID: PMC8861915          DOI: 10.1089/thy.2021.0310

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  21 in total

1.  A novel classification system for patients with PTC: addition of the new variables of large (3 cm or greater) nodal metastases and reclassification during the follow-up period.

Authors:  Iwao Sugitani; Nobukatsu Kasai; Yoshihide Fujimoto; Akio Yanagisawa
Journal:  Surgery       Date:  2004-02       Impact factor: 3.982

2.  Risk Stratification in Differentiated Thyroid Cancer: From Detection to Final Follow-up.

Authors:  R Michael Tuttle; Ali S Alzahrani
Journal:  J Clin Endocrinol Metab       Date:  2019-03-15       Impact factor: 5.958

3.  Active surveillance in papillary thyroid carcinoma: not easily accepted but possible in Latin America.

Authors:  Anabella Smulever; Fabián Pitoia
Journal:  Arch Endocrinol Metab       Date:  2019-09-02       Impact factor: 2.309

4.  A clinical framework to facilitate selection of patients with differentiated thyroid cancer for active surveillance or less aggressive initial surgical management.

Authors:  R Michael Tuttle; Ling Zhang; Ashok Shaha
Journal:  Expert Rev Endocrinol Metab       Date:  2018-03-14

5.  Active Surveillance for Patients With Papillary Thyroid Microcarcinoma: A Single Center's Experience in Korea.

Authors:  Hyemi Kwon; Hye-Seon Oh; Mijin Kim; Suyeon Park; Min Ji Jeon; Won Gu Kim; Won Bae Kim; Young Kee Shong; Dong Eun Song; Jung Hwan Baek; Ki-Wook Chung; Tae Yong Kim
Journal:  J Clin Endocrinol Metab       Date:  2017-06-01       Impact factor: 5.958

6.  Does postoperative thyrotropin suppression therapy truly decrease recurrence in papillary thyroid carcinoma? A randomized controlled trial.

Authors:  Iwao Sugitani; Yoshihide Fujimoto
Journal:  J Clin Endocrinol Metab       Date:  2010-07-21       Impact factor: 5.958

Review 7.  Surgical considerations for papillary thyroid microcarcinomas.

Authors:  Laura Boucai; Victor Bernet; Ashok Shaha; Maisie L Shindo; Brendan C Stack; Robert M Tuttle
Journal:  J Surg Oncol       Date:  2017-05-17       Impact factor: 3.454

8.  Active Surveillance in Papillary Thyroid Microcarcinomas is Feasible and Safe: Experience at a Single Italian Center.

Authors:  Eleonora Molinaro; Maria Cristina Campopiano; Letizia Pieruzzi; Antonio Matrone; Laura Agate; Valeria Bottici; David Viola; Virginia Cappagli; Laura Valerio; Carlotta Giani; Luciana Puleo; Loredana Lorusso; Paolo Piaggi; Liborio Torregrossa; Fulvio Basolo; Paolo Vitti; R Michael Tuttle; Rossella Elisei
Journal:  J Clin Endocrinol Metab       Date:  2020-03-01       Impact factor: 5.958

9.  Management of the recurrent laryngeal nerve in suspected and proven thyroid cancer.

Authors:  S A Falk; T V McCaffrey
Journal:  Otolaryngol Head Neck Surg       Date:  1995-07       Impact factor: 5.591

10.  Clinical Trials of Active Surveillance of Papillary Microcarcinoma of the Thyroid.

Authors:  Akira Miyauchi
Journal:  World J Surg       Date:  2016-03       Impact factor: 3.352

View more
  1 in total

Review 1.  [Hemithyroidectomy or total thyroidectomy for low-risk papillary thyroid cancer? : Surgical criteria for primary and secondary choice of treatment in an interdisciplinary treatment concept].

Authors:  H Dralle; F Weber; A Machens; T Brandenburg; K W Schmid; D Führer-Sakel
Journal:  Chirurgie (Heidelb)       Date:  2022-09-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.